Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity".
Zydus Lifesciences Limited Press Release Aug 21 2026
Filed with NSE · · 2 pages · English
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Zydus Hospitals Sets New Benchmarks in High-Risk Pregnancy and Complex Gynaecological Care
- Zydus Lifesciences Limited Press Release Aug 11 2026
- Zydus Lifesciences Limited Press Release Aug 04 2026
- Zydus Lifesciences Limited Press Release Aug 01 2026
- Zydus Lifesciences Limited Press Release Jul 23 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Aug 31 2026
- Zydus Lifesciences Limited Press Release Sep 26 2026
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences